Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1.
S1, a new chromogenic cephalosporin (International BioClinical, Inc., Portland, Oreg.), was used to detect beta-lactamase production among a variety of commonly encountered bacteria in a four-center collaborative study. Results of an S1 disk assay were compared with those obtained by a nitrocefin-ba...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1995
|
| _version_ | 1797070721395982336 |
|---|---|
| author | Doern, G Jones, R Gerlach, E Washington, J Biedenbach, D Brueggemann, A Erwin, M Knapp, C Raymond, J |
| author_facet | Doern, G Jones, R Gerlach, E Washington, J Biedenbach, D Brueggemann, A Erwin, M Knapp, C Raymond, J |
| author_sort | Doern, G |
| collection | OXFORD |
| description | S1, a new chromogenic cephalosporin (International BioClinical, Inc., Portland, Oreg.), was used to detect beta-lactamase production among a variety of commonly encountered bacteria in a four-center collaborative study. Results of an S1 disk assay were compared with those obtained by a nitrocefin-based disk procedure (Cefinase; Becton-Dickinson Microbiology Systems, Cockeysville, Md.), with repetitive testing of five quality control organisms and with individual tests of recent clinical isolates of Neisseria gonorrhoeae (162 strains), Haemophilus influenzae (162 strains), Moraxella catarrhalis (155 strains), Staphylococcus aureus (161 strains), and Bacteroides fragilis (164 strains). The performances of the two beta-lactamase disk assays were comparable for the first three species cited above. However, the S1 assay appeared to be a more sensitive procedure than the Cefinase assay when applied to S. aureus and B. fragilis, with respect to both total numbers of positive results and length of time to a definitive positive endpoint. |
| first_indexed | 2024-03-06T22:43:01Z |
| format | Journal article |
| id | oxford-uuid:5c3e595d-c9a5-4758-a121-e16f078b810c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:43:01Z |
| publishDate | 1995 |
| record_format | dspace |
| spelling | oxford-uuid:5c3e595d-c9a5-4758-a121-e16f078b810c2022-03-26T17:26:56ZMulticenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5c3e595d-c9a5-4758-a121-e16f078b810cEnglishSymplectic Elements at Oxford1995Doern, GJones, RGerlach, EWashington, JBiedenbach, DBrueggemann, AErwin, MKnapp, CRaymond, JS1, a new chromogenic cephalosporin (International BioClinical, Inc., Portland, Oreg.), was used to detect beta-lactamase production among a variety of commonly encountered bacteria in a four-center collaborative study. Results of an S1 disk assay were compared with those obtained by a nitrocefin-based disk procedure (Cefinase; Becton-Dickinson Microbiology Systems, Cockeysville, Md.), with repetitive testing of five quality control organisms and with individual tests of recent clinical isolates of Neisseria gonorrhoeae (162 strains), Haemophilus influenzae (162 strains), Moraxella catarrhalis (155 strains), Staphylococcus aureus (161 strains), and Bacteroides fragilis (164 strains). The performances of the two beta-lactamase disk assays were comparable for the first three species cited above. However, the S1 assay appeared to be a more sensitive procedure than the Cefinase assay when applied to S. aureus and B. fragilis, with respect to both total numbers of positive results and length of time to a definitive positive endpoint. |
| spellingShingle | Doern, G Jones, R Gerlach, E Washington, J Biedenbach, D Brueggemann, A Erwin, M Knapp, C Raymond, J Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1. |
| title | Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1. |
| title_full | Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1. |
| title_fullStr | Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1. |
| title_full_unstemmed | Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1. |
| title_short | Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1. |
| title_sort | multicenter clinical laboratory evaluation of a beta lactamase disk assay employing a novel chromogenic cephalosporin s1 |
| work_keys_str_mv | AT doerng multicenterclinicallaboratoryevaluationofabetalactamasediskassayemployinganovelchromogeniccephalosporins1 AT jonesr multicenterclinicallaboratoryevaluationofabetalactamasediskassayemployinganovelchromogeniccephalosporins1 AT gerlache multicenterclinicallaboratoryevaluationofabetalactamasediskassayemployinganovelchromogeniccephalosporins1 AT washingtonj multicenterclinicallaboratoryevaluationofabetalactamasediskassayemployinganovelchromogeniccephalosporins1 AT biedenbachd multicenterclinicallaboratoryevaluationofabetalactamasediskassayemployinganovelchromogeniccephalosporins1 AT brueggemanna multicenterclinicallaboratoryevaluationofabetalactamasediskassayemployinganovelchromogeniccephalosporins1 AT erwinm multicenterclinicallaboratoryevaluationofabetalactamasediskassayemployinganovelchromogeniccephalosporins1 AT knappc multicenterclinicallaboratoryevaluationofabetalactamasediskassayemployinganovelchromogeniccephalosporins1 AT raymondj multicenterclinicallaboratoryevaluationofabetalactamasediskassayemployinganovelchromogeniccephalosporins1 |